Immunosuppressant drugs or anti-rejection drugs are a class of drugs that suppress or reduce the strength of the body’s immune system. There are 2 types of immunosuppressants: Induction drugs: Powerful antirejection medicine used at the time of transplant and Maintenance drugs: antirejection medications used for the long term. Organ transplant immunosuppressant drugs are used by patients who are undergoing or have undergone an organ transplant for kidney, liver, heart, etc. due to organ dysfunction caused due to cancer, severe injuries to the organ, metabolic disorders such as renal failure and/or genetic disorders. Increasing number of organ transplantations globally and its demand for advanced immunosuppressant drugs for improved organ tolerance are the key factors driving the growth of the global organ transplant immunosuppressant drugs market. There are usually four classes of maintenance drugs: calcineurin inhibitors: tacrolimus and cyclosporine, antiproliferative agents: mycophenolate mofetil, mycophenolate sodium and azathioprine, mTOR inhibitor: sirolimus, and steroids: prednisone.
The global organ transplant immunosuppressant drugs market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug classes (calcineurin inhibitors: tacrolimus and cyclosporine, antiproliferative agents: mycophenolate mofetil, mycophenolate sodium and azathioprine, mTOR inhibitor: sirolimus, and steroids: prednisone) and transplanted organ types (bone marrow, heart, kidney liver and lung transplants), and forecasts growth trends (CAGR% – 2017 to 2021).
The global organ transplant immunosuppressant drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global organ transplant immunosuppressant drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global organ transplant immunosuppressant drugs market and included in this report are AbbVie, Inc., Astellas Pharma, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Genzyme Corporation (Sanofi S.A.), GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. and Veloxis Pharmaceuticals A/S.